home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next

Development of CAR-T Cells for T-ALL Targeting CCR9

  January 24, 2024  
Xtalks, Online

Discover a groundbreaking webinar exploring the developments in cancer immunotherapy targeting CC chemokine receptor 9 (CCR9), a potential breakthrough for T-cell acute lymphoblastic leukemia (T-ALL). CCR9 is a potential cancer immunotherapy target, expressed in the majority of cases of T-ALL but only in a small proportion of normal immune and thymic cells. Thus, an immunotherapy targeted against CCR9 may be able to kill T-ALL cells while preserving critical normal T cells. GenScript has recently demonstrated that chimeric antigen receptor (CAR)-T cells targeting CCR9 were potent in in vitro and murine models of T-ALL and will shortly commence a Phase I clinical trial of anti-CCR9 CAR-T in relapsed or refractory T-ALL.

CCR9 is a complex and challenging target antigen. It is a G-protein coupled receptor with seven transmembrane domains. There is high homology between rodent and human sequences with most differences located intracellularly or at the amino terminus. Thus, developing specific antibodies to CCR9 is difficult, and a previous rat vaccination yielded only a single antibody clone.


Join this webinar to gain insights into advancements in T-ALL immunotherapy using CAR-T cells targeting the CCR9 receptor.

Keywords: Immunotherapy, Leukemia, Preclinical, CRO, Oncology, CAR-T, CAR-T Immunotherapy, Preclinical Oncology, Acute Lymphoblastic Leukemia, Pre-Clinical
Organized by: Xtalks
Invited Speakers: Paul Maciocia, Clinical Scientist and Honorary Consultant Haematologist, Cancer Institute, University College London
Deadline for Abstracts: 2024-03-06
Registration: Free Registration
E-mail: tristan@xtalks.com
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.